Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

640
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
640
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

2.4K
The pathophysiology of pneumonia involves the following steps:
2.4K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

3.3K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

707
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
707
Pneumonia IV: Management01:28

Pneumonia IV: Management

665
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
665
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

149
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
149

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Viral infectivity in paediatric SARS-CoV-2 clinical samples does not vary by age.

Access microbiology·2023
Same author

Viral infectivity in pediatric SARS-CoV-2 clinical samples does not vary by age.

medRxiv : the preprint server for health sciences·2022
Same author

Blastomycosis in 64 Wisconsin Children: Unanticipated Infection Risk and Severity in Urban Residents.

The Pediatric infectious disease journal·2021
Same author

Inhibition of Human Coronaviruses by Antimalarial Peroxides.

ACS infectious diseases·2021
Same author

COVID-19 pre-procedural testing strategy and early outcomes at a large tertiary care children's hospital.

Pediatric surgery international·2021
Same author

Sequencing and analysis of globally obtained human parainfluenza viruses 1 and 3 genomes.

PloS one·2019

Related Experiment Video

Updated: Dec 24, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K

Viral pneumonia in children.

Kelly J Henrickson1

  • 1Medical College of Wisconsin, MACC Fund Research Center, Milwaukee, WI, USA.

Seminars in Pediatric Infectious Diseases
|April 15, 2020
PubMed
Summary

Viral pneumonia poses a significant societal burden, particularly in children. Advances in diagnostics and understanding viral variations are crucial for developing future vaccines and treatments.

Area of Science:

  • Pediatrics
  • Virology
  • Infectious Diseases

Background:

  • Viral pneumonia affects over a million children under 5 annually in the US, incurring substantial costs.
  • Common viruses are the primary cause, necessitating improved diagnostic and epidemiological understanding.
  • Recent molecular techniques reveal significant antigenic and genetic variations in previously homogenous viruses.

Purpose of the Study:

  • To highlight the societal impact of viral pneumonia.
  • To emphasize the role of epidemiology and rapid diagnostics in future diagnoses.
  • To discuss the implications of viral variations on vaccine and antiviral drug development.

Main Methods:

  • Review of existing epidemiological data on common viral pneumonia agents.
  • Analysis of emerging molecular techniques for viral characterization.

More Related Videos

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.9K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.2K

Related Experiment Videos

Last Updated: Dec 24, 2025

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

15.5K
A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness
12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

2.9K
An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

8.2K
  • Examination of current and developing antiviral therapies and prophylaxis.

    • Main Results:

    • Viral genetic and antigenic variations are increasingly identified, impacting pathogenicity and immunogenicity.
    • Existing treatments include prophylaxis for influenza A and respiratory syncytial virus (RSV).
    • Ribarivin is approved for RSV infections, with potential benefits in immunocompromised patients.

    Conclusions:

    • Understanding viral epidemiology and variations is key to combating pneumonia.
    • New molecular insights will drive the development of targeted vaccines and antiviral drugs.
    • Ongoing research into novel antiviral agents offers promise for improved patient outcomes.